USP7, Macrophage Polarization, and PKM2-Mediated Metabolic Reprogramming in Severe Acute Pancreatitis

Study Background and Research Question

Severe acute pancreatitis (SAP) is a critical inflammatory condition characterized by high morbidity and mortality, frequently leading to systemic inflammatory response syndrome and multi-organ failure. Despite its clinical severity, effective pharmacological interventions for SAP remain lacking. A defining feature of SAP pathogenesis is the dynamic infiltration and polarization of macrophages. Pro-inflammatory M1 macrophages dominate early disease phases, exacerbating tissue damage, while a subsequent shift toward anti-inflammatory M2 macrophages is associated with inflammation resolution and tissue repair (reference). Understanding the molecular mechanisms that govern macrophage polarization is crucial for identifying new therapeutic targets for SAP.

Key Innovation from the Reference Study

The pivotal innovation of this study is the identification of ubiquitin-specific protease 7 (USP7) as a central regulator of macrophage polarization through modulation of PKM2-mediated metabolic reprogramming. The research demonstrates that USP7 is upregulated in pancreatic macrophages during SAP and promotes the polarization of these cells toward the pro-inflammatory M1 phenotype. Mechanistically, USP7 regulates the deubiquitination and activity of pyruvate kinase M2 (PKM2), a glycolytic enzyme whose conformational state determines the balance between glycolysis and oxidative phosphorylation in macrophages. This work provides the first direct evidence that targeting the USP7–PKM2 axis can modulate immune cell metabolism and inflammatory responses in SAP (reference).

Methods and Experimental Design Insights

To dissect the role of USP7 in SAP, the authors employed a multifaceted approach integrating in vivo murine models, ex vivo tissue analysis, and in vitro cell culture systems:

• Expression Analysis: USP7 levels were quantified in pancreatic macrophages from SAP and control mice using immunofluorescence, Western blotting, and histological methods.
• Macrophage Phenotyping: Flow cytometry and immunostaining were used to distinguish M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophage populations.
• Functional Assays: Serum amylase and lipase activities, along with pro-inflammatory cytokine levels, were measured to assess the severity of pancreatitis and systemic inflammation.
• Metabolic Profiling: Seahorse extracellular flux assays were conducted to determine extracellular acidification rate (ECAR) and oxygen consumption rate (OCR), reflecting glycolytic and oxidative phosphorylation activities, respectively.
• Protein–Protein Interactions: Co-immunoprecipitation (Co-IP) and ubiquitinated immunoprecipitation assays were performed to define the interaction and regulatory relationship between USP7 and PKM2.
• Pharmacological Interventions: A PKM2 inhibitor was administered to SAP mice to probe the functional importance of PKM2 in mediating the effects of USP7 knockdown. Knockdown models were generated using established genetic techniques (reference).

Core Findings and Why They Matter

The study’s central findings can be summarized as follows:

• USP7 Upregulation in SAP: USP7 expression was significantly increased in pancreatic macrophages from SAP mice. This upregulation correlated with heightened inflammatory markers and disease severity.
• USP7 Drives M1 Polarization and Inflammation: USP7 knockdown in SAP mice resulted in a marked reduction in serum amylase and lipase, as well as decreased expression of pro-inflammatory cytokines. Importantly, the loss of USP7 shifted macrophage populations from the M1 to the M2 phenotype both in vivo and in vitro (reference).
• Metabolic Reprogramming via PKM2: The study elucidates that USP7 regulates PKM2 through deubiquitination, influencing its phosphorylation status and nuclear translocation. This, in turn, controls the metabolic state of macrophages: promoting glycolysis and the inflammatory M1 phenotype when USP7 is active, or facilitating OXPHOS and M2 polarization when USP7 is inhibited.
• Functional Reversal by PKM2 Inhibition: Administration of a PKM2 inhibitor partially reversed the protective effects observed with USP7 knockdown, confirming that PKM2 acts downstream of USP7 in this pathway. This pharmacological rescue experiment provides strong evidence that targeting glycolytic metabolism—specifically via pyruvate kinase M2 inhibitors—can modulate immune cell function in inflammatory disease contexts (reference).

Collectively, these results position the USP7–PKM2 axis as a critical metabolic checkpoint in the regulation of macrophage-driven inflammation in SAP, with broader implications for immunometabolism and inflammatory disease therapeutics.

Comparison with Existing Internal Articles

Several recent internal articles have highlighted the utility of PKM2 inhibitor (compound 3k) in various contexts of cancer and immune cell metabolism:

• "PKM2 Inhibitor (Compound 3k): Precision Disruption of Cancer Cell Metabolism" demonstrates the compound’s ability to selectively block glycolysis in tumor cells, facilitating studies in oncology and immunometabolism (internal article).
• "Targeting PKM2 in Cancer and Beyond: Mechanistic Insights" discusses the broader applicability of PKM2 inhibition in immune cell reprogramming, drawing parallels to the macrophage-focused findings of the current reference study.
• Comparatively, the reference paper provides direct in vivo evidence for the role of PKM2 in inflammatory macrophage polarization, extending the relevance of selective PKM2 inhibitors to non-oncological disease models and highlighting their utility in dissecting metabolic regulation in immune cells.

Limitations and Transferability

While the study robustly establishes the USP7–PKM2 axis as a modulator of macrophage polarization in murine SAP models, several limitations should be considered:

• Species Specificity: All in vivo experiments were conducted in mice; the extent to which these findings translate to human SAP or other inflammatory conditions remains to be validated.
• Complexity of Inflammatory Networks: SAP pathogenesis involves multifactorial immune and non-immune processes; targeting a single metabolic pathway may have limited efficacy in clinical settings.
• Pharmacological Tool Validation: While the study used a PKM2 inhibitor to confirm downstream effects, further characterization of inhibitor selectivity and off-target profiles is advisable for future translational work (reference).

Still, the strong mechanistic evidence and pharmacological intervention data provide a solid foundation for further research into metabolic modulation of macrophage phenotypes in inflammation.

Protocol Parameters

• animal model (SAP induction in mice) | 5–8-week-old BALB/c mice | SAP and inflammation studies | Standardized model for acute pancreatitis | literature (reference)
• inhibitor dosage (PKM2 inhibitor) | 5 mg/kg per 2 days (oral, 31 days) | in vivo metabolic modulation | Demonstrated efficacy in tumor and inflammation models | product_spec (spec)
• metabolic assay | Seahorse ECAR/OCR analysis | glycolytic and OXPHOS profiling | Sensitive detection of metabolic shifts in immune cells | literature (reference)
• PKM2 inhibitor concentration (cell culture) | 0.18–1.56 μM (IC₅₀ in cancer lines) | in vitro metabolic blockade | Reference for starting concentrations in immune cell studies | product_spec (spec)

Research Support Resources

Researchers interested in probing the metabolic regulation of immune cell phenotypes or modeling aerobic glycolysis disruption in inflammatory and cancer contexts can leverage PKM2 inhibitor (compound 3k) (SKU B8217), a selective pyruvate kinase M2 inhibitor validated for potency and specificity in both oncology and immunometabolic workflows (source: internal article). Its established use in cancer cell and immune cell studies offers a practical foundation for researchers extending the findings of this reference study into new disease models or therapeutic screens.